Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/59804
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Type: | Journal article |
Title: | IGF1 and its binding proteins 3 and 1 are differentially associated with metabolic syndrome in older men |
Author: | Yeap, Bu B. Chubb, S. A. Paul Ho, Ken K. Y. Setoh, Johnson W. S. McCaul, Kieran Anthony Norman, Paul E. Jamrozik, Konrad Flicker, Leon |
Citation: | European Journal of Endocrinology, 2010; 162(2):249-257 |
Publisher: | Bio Scientifica Ltd |
Issue Date: | 2010 |
ISSN: | 0804-4643 |
School/Discipline: | School of Population Health and Clinical Practice : Public Health |
Statement of Responsibility: | Bu B Yeap, S A Paul Chubb, Ken K Y Ho, Johnson W S Setoh, Kieran A McCaul, Paul E Norman, Konrad Jamrozik and Leon Flicker |
Abstract: | Objective: Circulating IGF1 declines with age, and reduced circulating IGF1 is associated with increased cardiovascular mortality in some but not all studies. The relationship between IGF-binding proteins 3 and 1 (IGFBP3 and IGFBP1) with risk of cardiovascular disease remains unclear. We sought to examine associations between IGF1, IGFBP3 and IGFBP1 with metabolic syndrome in older men. Design: Cross-sectional analysis of 3980 community-dwelling men aged 70 years. Methods: Morning plasma levels of IGF1, IGFBP3 and IGFBP1 were assayed. Metabolic syndrome was defined according to National Cholesterol Education Program-Adult Treatment Panel III (NCEP-ATPIII) criteria. Results: For IGF1 and IGFBP3, there was a U-shaped relationship, with middle quintiles possessing the lowest odds ratios (OR) for metabolic syndrome (reference Q1, Q3 IGF1: OR 0.74, 95% confidence intervals 0.57–0.96, Q3 IGFBP3: OR 0.67, 0.51–0.87). Increasing IGFBP1 was associated with reduced risk of metabolic syndrome with a dose–response gradient (reference Q1, OR for Q2 to Q5 IGFBP1: 0.56, 0.33, 0.22 and 0.12 respectively, P<0.001). IGF1 was associated with two, IGFBP1 with four and IGFBP3 with all five components of the metabolic syndrome. The ratio of IGF1/IGFBP3 was not associated with metabolic syndrome. Conclusions: In older men, both lower and higher IGF1 and IGFBP3 levels may be metabolically unfavourable. IGFBP1, as a marker of insulin sensitivity, is relevant in the assessment of metabolic syndrome, while the IGF1/IGFBP3 ratio is less informative. Longitudinal follow-up of this cohort would be needed to determine whether these distributions of IGF1, IGFBP3 and IGFBP1 predict incidence of cardiovascular events during male ageing. |
Description: | Copyright © 2010 by European Society of Endocrinology |
DOI: | 10.1530/EJE-09-0852 |
Appears in Collections: | Public Health publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.